KR20220088700A - 국소 진행성 편평 상피 세포 암종을 가진 환자를 치료하기 위한 투여 용법 - Google Patents
국소 진행성 편평 상피 세포 암종을 가진 환자를 치료하기 위한 투여 용법 Download PDFInfo
- Publication number
- KR20220088700A KR20220088700A KR1020227013744A KR20227013744A KR20220088700A KR 20220088700 A KR20220088700 A KR 20220088700A KR 1020227013744 A KR1020227013744 A KR 1020227013744A KR 20227013744 A KR20227013744 A KR 20227013744A KR 20220088700 A KR20220088700 A KR 20220088700A
- Authority
- KR
- South Korea
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- compound
- administered
- human patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905703P | 2019-09-25 | 2019-09-25 | |
| US62/905,703 | 2019-09-25 | ||
| US202063016762P | 2020-04-28 | 2020-04-28 | |
| US63/016,762 | 2020-04-28 | ||
| EP20184601 | 2020-07-07 | ||
| EP20184601.1 | 2020-07-07 | ||
| PCT/EP2020/076994 WO2021058794A1 (en) | 2019-09-25 | 2020-09-25 | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220088700A true KR20220088700A (ko) | 2022-06-28 |
Family
ID=72644266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227013744A Ceased KR20220088700A (ko) | 2019-09-25 | 2020-09-25 | 국소 진행성 편평 상피 세포 암종을 가진 환자를 치료하기 위한 투여 용법 |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024022275A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2525585T3 (es) | 2006-05-05 | 2014-12-26 | The Regents Of The University Of Michigan | Intermedios para la preparación de miméticos de SMAC bivalentes |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| WO2008014229A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| EP2296650B1 (en) | 2008-05-16 | 2020-05-06 | Novartis AG | Immunomodulation by iap inhibitors |
| US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| EP2493879B1 (en) | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant)) |
| US8859541B2 (en) | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| AU2013306087B2 (en) | 2012-08-23 | 2017-08-10 | The Regents Of The University Of Michigan | Bivalent inhibitors of IAP proteins and therapeutic methods using the same |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| WO2014121178A1 (en) | 2013-02-04 | 2014-08-07 | Tetralogic Pharmaceuticals Corp. | Smac mimetic method of treatment |
| US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
| US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| AU2015360095B2 (en) * | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| CA2916970A1 (en) | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
| EP3419643A4 (en) | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
| CN110475567A (zh) | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| WO2019122941A1 (en) * | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
-
2020
- 2020-09-25 AU AU2020356356A patent/AU2020356356A1/en not_active Abandoned
- 2020-09-25 CA CA3151770A patent/CA3151770A1/en active Pending
- 2020-09-25 CN CN202080079488.5A patent/CN114727984A/zh active Pending
- 2020-09-25 WO PCT/EP2020/076994 patent/WO2021058794A1/en not_active Ceased
- 2020-09-25 MX MX2022003628A patent/MX2022003628A/es unknown
- 2020-09-25 EP EP20780195.2A patent/EP4034102A1/en not_active Withdrawn
- 2020-09-25 US US17/761,503 patent/US20250268863A1/en not_active Abandoned
- 2020-09-25 BR BR112022005624A patent/BR112022005624A2/pt not_active IP Right Cessation
- 2020-09-25 PH PH1/2022/550721A patent/PH12022550721A1/en unknown
- 2020-09-25 JP JP2022518772A patent/JP2022550037A/ja active Pending
- 2020-09-25 KR KR1020227013744A patent/KR20220088700A/ko not_active Ceased
-
2022
- 2022-03-24 IL IL291682A patent/IL291682A/en unknown
- 2022-04-20 CO CONC2022/0004947A patent/CO2022004947A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250268863A1 (en) | 2025-08-28 |
| PH12022550721A1 (en) | 2024-05-13 |
| AU2020356356A1 (en) | 2022-05-12 |
| IL291682A (en) | 2022-05-01 |
| MX2022003628A (es) | 2022-07-21 |
| CA3151770A1 (en) | 2021-04-01 |
| CO2022004947A2 (es) | 2022-08-30 |
| EP4034102A1 (en) | 2022-08-03 |
| CN114727984A (zh) | 2022-07-08 |
| WO2021058794A1 (en) | 2021-04-01 |
| JP2022550037A (ja) | 2022-11-30 |
| BR112022005624A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP6805336B2 (ja) | 薬学的組み合わせ | |
| JP2016523858A (ja) | がんを治療するためのbtk阻害剤とフルオロウラシルとの併用 | |
| US20250127759A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer | |
| Gauler et al. | Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| CN115803629A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| US20250268863A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| RU2854294C2 (ru) | Ингибитор cdk4 для лечения рака | |
| WO2024121861A1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| EA049513B1 (ru) | Ингибитор egfr для лечения рака головы и шеи | |
| Stein et al. | What Chemotherapy | |
| CN112770759A (zh) | 用于治疗伴脑转移的晚期非小细胞肺癌患者的组合药物 | |
| CN114667159A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| NZ625611B2 (en) | Combination treatment of cancer | |
| NZ625611A (en) | Combination treatment of cancer | |
| TW201311247A (zh) | 包括末期或轉移固態惡性腫瘤之固態惡性腫瘤治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |